Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Soiken HoldingsTSE:2385 +1.40%58 Return-on-Tangible-Asset is 0.00% as of Dec. 2025. GuruFocus rates TSE:2385 with a GF Score™ of 58/100 and a GF Value™ of 円93.84 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Soiken Holdings ranks better than 82.66% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Soiken Holdings's annualizedNet Income for the quarter that ended in Dec. 2025 was 円0 Mil. Soiken Holdings's average total tangible assets for the quarter that ended in Dec. 2025 was 円6,716 Mil. Therefore, Soiken Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Soiken Holdings's Return-on-Tangible-Asset or its related term are showing as below:
TSE:2385'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.76 Med: 4.51 Max: 10.76
Current: 1.57
During the past 13 years, Soiken Holdings's highest Return-on-Tangible-Asset was 10.76%. The lowest was -8.76%. And the median was 4.51%.
TSE:2385's Return-on-Tangible-Asset is ranked better than 82.66% of 1413
companies
in the Biotechnology industry
Industry Median: -35.75
vs TSE:2385: 1.57
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Soiken Holdings Return-on-Tangible-Asset Related Terms
Soiken Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Soiken Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2385 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Soiken Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 0.00% mean?
Soiken Holdings (TSE:2385) has a Return-on-Tangible-Asset of 0.00% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Soiken Holdings and its competitors. According to the industry distribution chart, Soiken Holdings ranks #245 out of 1413 companies in the Biotechnology industry, placing it in the top 17.3%.
Is Soiken Holdings' Return-on-Tangible-Asset too high?
Soiken Holdings' current Return-on-Tangible-Asset is 0.00%. Based on the distribution chart, Soiken Holdings ranks #245 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soiken Holdings has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #245 out of 1413 companies for Return-on-Tangible-Asset. This places Soiken Holdings in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Soiken Holdings and its competitors. Soiken Holdings's current Return-on-Tangible-Asset is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円93.84, compared to a current price of 円218.00 — trading 132.3% above its estimated fair value. The current Return-on-Tangible-Asset is 0.00%. Soiken Holdings' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current Return-on-Tangible-Asset is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円218.00 is trading 132.3% above its estimated GF Value™ of 円93.84.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
Return-on-Tangible-Asset: 0.00%
GF Value™: 円93.84 vs. price of 円218.00 (132.3% above fair value)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
58GF Score
Get the complete analysis for TSE:2385
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
